

Timothy Iveson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4636687/publications.pdf>

Version: 2024-02-01

21
papers

5,803
citations

623574

14
h-index

713332

21
g-index

21
all docs

21
docs citations

21
times ranked

6796
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2048-2057.	0.8	65
2	Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100445.	0.7	1
3	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 631-641.	0.8	63
4	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2021, 22, 690-701.	5.1	396
5	Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e288-e289.	5.1	2
6	Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa107.	1.4	2
7	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4019.	0.8	45
8	Adjuvant chemotherapy in colon cancer: state of the art and future perspectives. <i>Current Opinion in Oncology</i> , 2020, 32, 370-376.	1.1	9
9	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf <i>Lancet Oncology</i> , The, 2020, 21, 1620-1629.	5.1	152
10	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 663-673.	5.1	773
11	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-88.	1.3	20
12	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1177-1188.	13.9	699
13	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1332-1338.	2.9	19
14	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA1-LBA1.	0.8	17
15	Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 333.	0.8	7
16	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. <i>British Journal of Cancer</i> , 2016, 114, 965-971.	2.9	39
17	A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014, 50, 3136-3144.	1.3	17
18	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 261-269.	1.0	94

#	ARTICLE	IF	CITATIONS
19	Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. <i>Trials</i> , 2011, 12, .	0.7	4
20	Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?. <i>Trials</i> , 2011, 12, .	0.7	9
21	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1273-1281.	13.9	3,370